pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Iwilfin
drug
save

eflornithine hydrochloride

Marketedupdated 3mo ago
by US WorldMeds LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagGlioblastoma4 co-mentions · 1 sources
  • drugeflornithine1 co-mentions · 1 sources
  • drugAMXT-1501 + eflornithine hydrochloride1 co-mentions · 1 sources
  • companyMayo Clinic1 co-mentions · 1 sources
  • tagOncology1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 3 investigational indications.

all catalysts(1)

phase 1 2 initiation · 1
Apr 24, 2026
phase 1 2 initiation
4mo ago
Mayo Clinic — eflornithine hydrochloride (Phase I/II Trial Initiation)
eflornithine hydrochloride
→

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 13, 2026
117 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (1)

  • Feb 12, 2036method-of-use (U-4444)US 12582625

FDA exclusivities (2)

  • Dec 13, 2030ODE-462Orphan Drug (7y)4.3y
  • Dec 13, 2026NPNP117d

News(0)

no news has mentioned this drug yet

brand
Iwilfin
generic
eflornithine hydrochloride
MOA
Ornithine decarboxylase inhibitor
indication
Neuroblastoma
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?